Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Dexlansoprazole; Esomeprazole; Lansoprazole

Criteria

Inclusion Criteria:

• Participants must be 18-70 years of age

• Participants can be male or female

• Women that are able to have children must have a negative pregnancy test.

Exclusion Criteria:

• Involvement in or planning of this study

• Participation in another clinical study within 28 days of this one

• For women, pregnancy or attempting to become pregnant.